Publications by authors named "Stephen Bain"

Claim this Profile
O
Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial.
Deborah B Horn, Donna H Ryan, Sanja Giljanovic Kis, Breno Alves, Yiming Mu, Stephen C Bain

Lancet· December 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Addressing the risk of ocular complications of GLP-1RAs; a multi-disciplinary expert consensus.
Patrice Carter, Rafael Simó, Monica Lövestam-Adrian, Ian Pearce, Stephen C Bain

Diabetes Obes Metab· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Using Artificial Intelligence to Improve the Accuracy of a Wrist-Worn, Noninvasive Glucose Monitor: A Pilot Study.
Muhammad Rafaqat Ali Qureshi, Stephen Charles Bain, Stephen Luzio, Consuelo Handy, Daniel J Fowles

J Diabetes Sci Technol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of British Clinical Diabetologists and UK Kidney Association Joint Clinical Practice Guidelines for the Pharmacological Management of Hyperglycemia in Adults With Type 2 Diabetes Mellitus and CKD.
Janaka Karalliedde, Kieran McCafferty, Peter Winocour, Tahseen A Chowdhury, Naresh Kanumilli, Stephen C Bain

Kidney Int Rep· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Insights on Hospitalisations from the Phase 3a ONWARDS 1-6 Trials of Once-Weekly Insulin Icodec.
Athena Philis-Tsimikas, Julie Krogsdahl Bache, Ariel Fu, Monika Kellerer, Karen Salvesen-Sykes, Stephen C Bain

Diabetes Ther· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oral Semaglutide and Cardiovascular Outcomes in People With Type 2 Diabetes, According to SGLT2i Use: Prespecified Analyses of the SOUL Randomized Trial.
Nikolaus Marx, John E Deanfield, Johannes F E Mann, Rosario Arechavaleta, Stephen C Bain

Circulation· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes.
Darren K McGuire, Nikolaus Marx, Sharon L Mulvagh, John E Deanfield, Silvio E Inzucchi, Stephen C Bain

N Engl J Med· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Current management of chronic kidney disease in type-2 diabetes-A tiered approach: An overview of the joint Association of British Clinical Diabetologists and UK Kidney Association (ABCD-UKKA) guidelines.
Indranil Dasgupta, Sagen Zac-Varghese, Khuram Chaudhry, Kieran McCafferty, Peter Winocour, Stephen C Bain

Diabet Med· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Finerenone in the management of diabetes kidney disease.
Parijat De, May T Khine, Andrew Frankel, Gabrielle Goldet, Debasish Banerjee, Stephen Bain

BMC Nephrol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cardiovascular, Metabolic, and Safety Outcomes with Semaglutide by Baseline Age: Post Hoc Analysis of SUSTAIN 6 and PIONEER 6.
Stephen C Bain, Nicolas Belmar, Søren T Hoff, Mansoor Husain, Søren Rasmussen

Diabetes Ther· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long term health outcomes in people with diabetes 12 months after hospitalisation with COVID-19 in the UK: a prospective cohort study.
Safoora Gharibzadeh, Ash Routen, Cameron Razieh, Francesco Zaccardi, Claire Lawson, Stephen C Bain

EClinicalMedicine· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Continuous measurement of interstitial glycaemia in professional female UCI world tour cyclists undertaking a 9-day cycle training camp.
Ross Hamilton, Olivia M McCarthy, Stephen C Bain, Richard M Bracken

Eur J Sport Sci· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of oral semaglutide vs sitagliptin in a predominantly Chinese population with type 2 diabetes uncontrolled with metformin: PIONEER 12, a double-blind, Phase IIIa, randomised trial.
Linong Ji, Rikke M Agesen, Stephen C Bain, Fangming Fu, Sanaz Gabery

Diabetologia· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of oral semaglutide monotherapy vs placebo in a predominantly Chinese population with type 2 diabetes (PIONEER 11): a double-blind, Phase IIIa, randomised trial.
Weiqing Wang, Stephen C Bain, Fang Bian, Rui Chen, Sanaz Gabery

Diabetologia· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Clinical Experience of Oral Semaglutide in a Secondary Diabetes Clinic in the UK: A Retrospective Observational Study.
David M Williams, Barbara-Alex Alberts, Asem Sharaf, Giselle Sharaf, Stephen C Bain

Diabetes Ther· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of Once-Weekly Semaglutide on Kidney Disease Outcomes by KDIGO Risk Category in the SUSTAIN 6 Trial.
Katherine R Tuttle, Stephen C Bain, Heidrun Bosch-Traberg, Kamlesh Khunti, Søren Rasmussen

Kidney Int Rep· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Regulation of Metabolic Homeostasis by Incretins and the Metabolic Hormones Produced by Pancreatic Islets.
Joshua Reed, Stephen C Bain, Venkateswarlu Kanamarlapudi

Diabetes Metab Syndr Obes· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative Analysis of Orthosteric and Allosteric GLP-1R Agonists' Effects on Insulin Secretion from Healthy, Diabetic, and Recovered INS-1E Pancreatic Beta Cells.
Joshua Reed, Victoria Higginbotham, Stephen Bain, Venkateswarlu Kanamarlapudi

Int J Mol Sci· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SGLT2 Inhibitors - The New Standard of Care for Cardiovascular, Renal and Metabolic Protection in Type 2 Diabetes: A Narrative Review.
Samuel Seidu, Vicki Alabraba, Sarah Davies, Philip Newland-Jones, Kevin Fernando, Stephen C Bain

Diabetes Ther· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Use of Oral and Subcutaneous Semaglutide in Routine Clinical Practice in the UK: A Single-Centre, Retrospective Observational Study.
Sharmistha Roy Chowdhury, Fethi Sadouki, Edward Collins, Frederick Keen, Ridhi Bhagi, Stephen C Bain

Diabetes Ther· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Glucagon-a new player in weight management therapeutics?
Stephen C Bain, David M Williams

Lancet Diabetes Endocrinol· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The authors reply.
Katherine R Tuttle, Heidrun Bosch-Traberg, David Z I Cherney, Samy Hadjadj, Ofri Mosenzon, Stephen C Bain

Kidney Int· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early use of oral semaglutide in the UK: A cost-effectiveness analysis versus continuing metformin and SGLT-2 inhibitor therapy.
Hongye Ren, Sasha Berry, Samuel Joseph Paul Malkin, Barnaby Hunt, Stephen Bain

BMJ Open· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A new class of glucose-lowering therapy for type 2 diabetes: the latest development in the incretin arena.
Stephen C Bain, Thinzar Min

Lancet· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of semaglutide on major adverse cardiovascular events by baseline kidney parameters in participants with type 2 diabetes and at high risk of cardiovascular disease: SUSTAIN 6 and PIONEER 6 post hoc pooled analysis.
Peter Rossing, Stephen C Bain, Heidrun Bosch-Traberg, Ekaterina Sokareva, Hiddo J L Heerspink

Cardiovasc Diabetol· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis